Biography
Arjen Slooter studied Medicine at the Vrije Universiteit, Amsterdam and was research fellow in
Neuro-Epidemiology at the G.H. Sergievsky Center, Columbia University, New York. He received a PhD in Epidemiology from Erasmus University, Rotterdam, on a thesis on dementia. After his residency in Neurology at UMC Utrecht and a fellowship in Intensive Care Medicine (AMC Amsterdam), he worked until 2022 as consultant neurologist-intensivist at the Department of Intensive Care Medicine of UMC Utrecht. In 2016, he was appointed as Professor of Intensive Care Neuropsychiatry at Utrecht University. Dr Slooter has been chair of the delirium section of the (American) Society of Critical Care Medicine (SCCM) guidelines on pain, agitation/sedation, delirium, immobility, and sleep disruption. In addition, he has been President of the European Delirium Association, and initiator and chair of an international consortium to update nomenclature on delirium and acute encephalopathy. After a career shift to psychiatry (UMC Utrecht), he is currently working as psychiatrist at UMCG, and as Professor of Consultation-Liaison Psychiatry at the University of Groningen.
Research
The research focus of Arjen Slooter is on delirium and on neuropsychiatric outcome after anesthesia/surgery or critical illness. Using various methods and approaches (epidemiology, EEG, MRI), he has investigated all aspects of delirium, including its phenomenology and brain network characteristics, detection and monitoring, risk factors, prognosis, prevention, and treatment. Research on neuropsychiatric outcomes includes risk factor analysis on cognitive decline, mental illness and chronic pain after critical illness and treatment in the ICU.
Key publications
1. Van den Boogaard M, Slooter AJC, Brüggemann RJM, Schoonhoven L, Beishuizen A, Vermeijden JW, Pretorius D, de Koning J, Simons KS, Dennesen PJW, Van der Voort PHJ, Houterman S, van der Hoeven JG, Pickkers P; REDUCE Study Investigators. Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium: The REDUCE Randomized Clinical Trial. JAMA 2018;319:680-90.
Impact factor 63.1, top 10% Medicine, General and Internal.
2. Numan T, van den Boogaard M, Kamper AM, Rood PJT, Peelen LM, Slooter AJC; Dutch Delirium Detection Study Group. Delirium detection using relative delta power based on 1-minute single-channel EEG: a multicentre study. Br J Anaesth 2019;122:60-8.
Impact factor 9.6, top 10% Anesthesiology.
3. Slooter AJC, Otte WM, Devlin JW, Arora RC, Bleck TP, Claassen J, Duprey MS, Ely EW, Kaplan PW, Latronico N, Morandi A, Neufeld KJ, Sharshar T, MacLullich AMJ, Stevens RD. Updated nomenclature of delirium and acute encephalopathy: statement of ten societies. Intensive Care Med 2020;46:1020-2.
Impact factor 41.8, top 10% Critical Care Medicine.
4. Wilson JE, Mart M, Cunningham C, Shehabi Y, Girard T, MacLullich A, Slooter AJC, EW Ely. Delirium. Nature Rev Dis Primers 2020;6:90.
Impact factor 81.5, top 10% Medicine, General and Internal.
5. Duprey MS, Dijkstra-Kersten SMA, Zaal IJ, Briesacher BA, Saczynski JS, Griffith JL, Devlin JW, Slooter AJC. Opioid use increases the risk of delirium in critically ill adults independently of pain. Am J Respir Crit Care Med 2021;204:566-72.
Impact factor 24.7, top 10% Critical Care Medicine.
Contact
E-mail a.slooter@umcg.nl